Monte Rosa Therapeutics, Inc. Shares Outstanding (Cover Page)
Monte Rosa Therapeutics, Inc. (GLUE) had Shares Outstanding (Cover Page) of 85.31 million shares as of 2026-07-31, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-06
- 2026-07-31: Entity Common Stock, Shares Outstanding 85.31M shares.
- 2026-05-01: Entity Common Stock, Shares Outstanding 84.48M shares.
- 2026-03-02: Entity Common Stock, Shares Outstanding 80.02M shares.
- 2025-10-31: Entity Common Stock, Shares Outstanding 65.12M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-07-31 | 85.31M shares 10-Q · filed 2026-08-06 |
| 2026-05-01 | 84.48M shares 10-Q · filed 2026-05-07 |
| 2026-03-02 | 80.02M shares 10-K · filed 2026-03-17 |
| 2025-10-31 | 65.12M shares 10-Q · filed 2025-11-06 |
| 2025-08-01 | 61.76M shares 10-Q · filed 2025-08-07 |
| 2025-05-05 | 61.51M shares 10-Q · filed 2025-05-08 |
| 2025-03-17 | 61.51M shares 10-K · filed 2025-03-20 |
| 2024-08-05 | 61.37M shares 10-Q · filed 2024-08-08 |
| 2024-05-06 | 50.51M shares 10-Q · filed 2024-05-09 |
| 2024-03-11 | 50.15M shares 10-K · filed 2024-03-14 |
| 2023-11-06 | 50.08M shares 10-Q · filed 2023-11-09 |
| 2023-05-08 | 49.38M shares 10-Q · filed 2023-05-11 |
| 2023-03-10 | 49.36M shares 10-K · filed 2023-03-16 |
| 2022-11-07 | 48.40M shares 10-Q · filed 2022-11-10 |
| 2022-08-05 | 46.71M shares 10-Q · filed 2022-08-11 |
| 2022-05-05 | 46.67M shares 10-Q · filed 2022-05-11 |
| 2022-03-25 | 46.63M shares 10-K · filed 2022-03-29 |
| 2021-11-09 | 46.51M shares 10-Q · filed 2021-11-10 |
| 2021-08-10 | 46.38M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |